Considering the presence of ULD of growth factors in MIM-4 formulation, hr-EGF (27 CH) and hr-TGF-β (27 CH) (see Table 1), and, as the rationale of this specific CH is the intention to disrupt EGF- and TGF-β-related-pathways in CRC cells, we wanted to avoid any exogenous supply of growth factors to the cancer cells, which are normally provided by fetal bovine serum (FBS). The gene discussed is TGFB1; the disease is colorectal carcinoma.